Results 11 to 20 of about 2,929 (206)

Tiered approach to evaluate the CYP3A victim and perpetrator drug–drug interaction potential for vonoprazan using PBPK modeling and clinical data to inform labeling

CPT: Pharmacometrics & Systems Pharmacology, 2023
Vonoprazan is metabolized extensively through CYP3A and is an in vitro time‐dependent inhibitor of CYP3A. A tiered approach was applied to understand the CYP3A victim and perpetrator drug–drug interaction (DDI) potential for vonoprazan.
Darcy J. Mulford, Diane Ramsden, Liming Zhang, Ingrid Michon, Eckhard Leifke, Neila Smith, Hannah M. Jones, Carmelo Scarpignato   +7 more
doaj   +1 more source

Influence of daily vs. alternate-day dosing of vonoprazan on intragastric pH, serum gastrin, and the antiplatelet function of clopidogrel [PDF]

, 2022
雑誌掲載タイトル：Influence of daily versus alternate-day dosing of vonoprazan on intragastric pH, serum gastrin, and the antiplatelet function of clopidogrelBackground: Vonoprazan, a potassium-competitive acid blocker, inhibits gastric acid secretion and ...
Furuta, Takahisa, Hamaya, Yasushi, Higuchi, Tomohiro, Iwaizumi, Moriya, Kagami, Takuma, Osawa, Satoshi, Sugimoto, Ken, Takahashi, Satoru, Tamura, Satoshi, Tani, Shinya, Uotani, Takahiro, Yamade, Mihoko   +11 more
core   +1 more source

Efficacy and safety of potassium-competitive acid blockers versus proton pump inhibitors as Helicobacter pylori eradication therapy: a meta-analysis of randomized clinical trials [PDF]

, 2022
Background and aims: Potassium-Competitive Acid Blockers (P-CABs) have been used in Helicobacter pylori (H. pylori) eradication therapies in recent years.
Pang, Mingge, Zhang, Mei, Zhang, Mengran
core   +2 more sources

Incidence and type of adverse events in patients taking vonoprazan: A systematic review and meta-analysis

Therapeutic Advances in Gastroenterology, 2023
Background: Vonoprazan, a novel acid-suppressive drug, is non-inferior to proton pump inhibitors (PPIs) for the management of gastric acid-related diseases. However, the safety of vonoprazan has not been systematically evaluated yet.
Wentao Xu, Zhaohui Bai, Yiyang Shang, Jing Wang, Yujun Wong, Xingshun Qi   +5 more
doaj   +1 more source

Randomised clinical trial: 3-year interim analysis results of the VISION trial to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive oesophagitis

BMC Gastroenterology, 2023
Background VISION is a randomised, phase 4, open-label, parallel-group, multicentre study conducted in 33 centres in Japan. The aim of this study was to assess the long-term safety of vonoprazan for maintenance treatment of healed erosive oesophagitis ...
Ken Haruma, Yoshikazu Kinoshita, Takashi Yao, Ryoji Kushima, Junichi Akiyama, Nobuo Aoyama, Tatsuhiro Kanoo, Kouji Miyata, Naomi Kusumoto, Naomi Uemura   +9 more
doaj   +1 more source

Potassium-Competitive Acid Blocker and Proton Pump Inhibitor–Based Regimens for First-Line Helicobacter pylori Eradication: A Network Meta-Analysis

Gastro Hep Advances, 2022
Background and Aims: Effective acid suppression is a crucial component of Helicobacter pylori (H. pylori) eradication regimens. Approved treatments include dual, triple, and quadruple therapies composed of certain antibiotics in combination with proton ...
Peter Malfertheiner, Steven F. Moss, Patrick Daniele, Corey Pelletier, Rinu Jacob, Gabriel Tremblay, Elizabeth Hubscher, Eckhard Leifke, William D. Chey   +8 more
doaj   +1 more source

Impact of Vonoprazan Triple-Drug Blister Packs on H. pylori Eradication Rates in Japan: Interrupted Time Series Analysis [PDF]

, 2021
INTRODUCTION: Helicobacter pylori eradication therapy requires a complex prescribing schedule combining clarithromycin, amoxicillin, and a proton-pump inhibitor (PPI) or potassium-competitive acid blocker (P-CAB, vonoprazan).
Deguchi, Hisato, Fukuhara, Shunichi, Kamitani, Tsukasa, Yamamoto, Yosuke, Yamazaki, Hajime   +4 more
core   +1 more source

Why the Vonoprazan Helicobacter pylori Therapies in the US-European Trial Produced Unacceptable Cure Rates [PDF]

, 2023
INTRODUCTION: Helicobacter pylori infects a large percentage of the world\u27s population and is etiologically related to gastric cancer. The U.S. Food and Drug Administration recently approved two 14-day vonoprazan-containing regimens (vonoprazan ...
Graham, David Y
core   +2 more sources

Fourteen-Day Vonoprazan and Low- or High-Dose Amoxicillin Dual Therapy for Eradicating Helicobacter pylori Infection: A Prospective, Open-Labeled, Randomized Non-inferiority Clinical Study [PDF]

, 2022
BACKGROUND AND AIM: We previously reported that vonoprazan-amoxicillin (VA) dual therapy for 7 or 10 days is not satisfactorily efficacious for METHODS: This was a single center, prospective, open-labeled, randomized non-inferiority clinical study ...
Graham, David Y, He, Cong, Hu, Yi, Li, Nian-Shuang, Liu, Xiao-Shun, Lu, Nong-Hua, Ouyang, Yao-Bin, Peng, Chao, Shu, Xu, Xie, Chuan, Xie, Yong, Xu, Xin, Zhu, Yin, Zhu, Zhen-Hua   +13 more
core   +2 more sources

Antibiotic susceptibility, heteroresistance, and updated treatment strategies in helicobacter pylori infection [PDF]

, 2017
In this review, we discuss the problem of antibiotic resistance, heteroresistance, the utility of cultures and antibiotic susceptibility tests in Helicobacter pylori (Hp) eradication, as well as the updated treatment strategies for this infection.
De Angelis, Massimiliano, Mascellino, Maria Teresa, Oliva, Alessandra, Porowska, Barbara   +3 more
core   +1 more source